Literature DB >> 28358947

MEKanisms of a Serous Complication.

Cynthia L Montana1, Rajendra S Apte2.   

Abstract

Mesh:

Substances:

Year:  2017        PMID: 28358947     DOI: 10.1001/jamaophthalmol.2017.0275

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   7.389


× No keyword cloud information.
  4 in total

1.  Ocular Toxicity Profile of ST-162 and ST-168 as Novel Bifunctional MEK/PI3K Inhibitors.

Authors:  Andrew Smith; Mercy Pawar; Marcian E Van Dort; Stefanie Galbán; Amanda R Welton; Greg M Thurber; Brian D Ross; Cagri G Besirli
Journal:  J Ocul Pharmacol Ther       Date:  2018-04-30       Impact factor: 2.671

2.  Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy.

Authors:  Jasmine H Francis; Larissa A Habib; David H Abramson; Lawrence A Yannuzzi; Murk Heinemann; Mrinal M Gounder; Rachel N Grisham; Michael A Postow; Alexander N Shoushtari; Ping Chi; Neil H Segal; Rona Yaeger; Alan L Ho; Paul B Chapman; Federica Catalanotti
Journal:  Ophthalmology       Date:  2017-07-12       Impact factor: 12.079

3.  High-yield, automated intracellular electrophysiology in retinal pigment epithelia.

Authors:  Colby F Lewallen; Qin Wan; Arvydas Maminishkis; William Stoy; Ilya Kolb; Nathan Hotaling; Kapil Bharti; Craig R Forest
Journal:  J Neurosci Methods       Date:  2019-09-25       Impact factor: 2.390

Review 4.  The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities.

Authors:  Laura J Klesse; Justin T Jordan; Heather B Radtke; Tena Rosser; Elizabeth Schorry; Nicole Ullrich; David Viskochil; Pamela Knight; Scott R Plotkin; Kaleb Yohay
Journal:  Oncologist       Date:  2020-04-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.